These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12925454)

  • 1. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
    Granger CB; Mahaffey KW; Weaver WD; Theroux P; Hochman JS; Filloon TG; Rollins S; Todaro TG; Nicolau JC; Ruzyllo W; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1184-90. PubMed ID: 12925454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
    Mahaffey KW; Granger CB; Nicolau JC; Ruzyllo W; Weaver WD; Theroux P; Hochman JS; Filloon TG; Mojcik CF; Todaro TG; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1176-83. PubMed ID: 12925455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction.
    Armstrong PW; Mahaffey KW; Chang WC; Weaver WD; Hochman JS; Theroux P; Rollins S; Todaro TG; Granger CB;
    Am Heart J; 2006 Apr; 151(4):787-90. PubMed ID: 16569534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
    ; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
    JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
    Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
    Mahaffey KW; Van de Werf F; Shernan SK; Granger CB; Verrier ED; Filloon TG; Todaro TG; Adams PX; Levy JH; Hasselblad V; Armstrong PW
    Am Heart J; 2006 Aug; 152(2):291-6. PubMed ID: 16875911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
    Verrier ED; Shernan SK; Taylor KM; Van de Werf F; Newman MF; Chen JC; Carrier M; Haverich A; Malloy KJ; Adams PX; Todaro TG; Mojcik CF; Rollins SA; Levy JH;
    JAMA; 2004 May; 291(19):2319-27. PubMed ID: 15150203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
    Théroux P; Armstrong PW; Mahaffey KW; Hochman JS; Malloy KJ; Rollins S; Nicolau JC; Lavoie J; Luong TM; Burchenal J; Granger CB
    Eur Heart J; 2005 Oct; 26(19):1964-70. PubMed ID: 15872036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Martel C; Granger CB; Ghitescu M; Stebbins A; Fortier A; Armstrong PW; Bonnefoy A; Theroux P
    Am Heart J; 2012 Jul; 164(1):43-51. PubMed ID: 22795281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention?
    Beranek JT
    Circulation; 2004 Apr; 109(16):e195-6; author reply e195-6. PubMed ID: 15117866
    [No Abstract]   [Full Text] [Related]  

  • 12. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.
    Testa L; Van Gaal WJ; Bhindi R; Biondi-Zoccai GG; Abbate A; Agostoni P; Porto I; Andreotti F; Crea F; Banning AP
    J Thorac Cardiovasc Surg; 2008 Oct; 136(4):884-93. PubMed ID: 18954626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.
    Mills JS; Mahaffey KW; Lokhnygina Y; Nicolau JC; Ruzyllo W; Adams PX; Todaro TG; Armstrong PW; Granger CB;
    Coron Artery Dis; 2012 Mar; 23(2):118-25. PubMed ID: 22217457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
    Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
    Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
    Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
    J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Trendelenburg M; Theroux P; Stebbins A; Granger C; Armstrong P; Pfisterer M
    Eur Heart J; 2010 May; 31(10):1181-7. PubMed ID: 20089518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass.
    Fleisig AJ; Verrier ED
    Expert Opin Biol Ther; 2005 Jun; 5(6):833-9. PubMed ID: 15952913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Buller CE; Fu Y; Mahaffey KW; Todaro TG; Adams P; Westerhout CM; White HD; van 't Hof AW; Van de Werf FJ; Wagner GS; Granger CB; Armstrong PW
    Circulation; 2008 Sep; 118(13):1335-46. PubMed ID: 18779444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Hudson MP; Armstrong PW; O'Neil WW; Stebbins AL; Weaver WD; Widimsky P; Aylward PE; Ruzyllo W; Holmes D; Mahaffey KW; Granger CB
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):183-92. PubMed ID: 21304097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.